Amicus Therapeutics (FOLD) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 8, 2023 7:00 AM EDT1H 2023 Revenue Growth of 16% at CER to $180.8M
Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER
EU Launch of Pombiliti® + Opfolda® Underway; U.S. and U.K. Approvals Expected 3Q 2023
Reducing 2023 Non-GAAP Operating Expense Guidance to $330M-$350M
Non-GAAP Profitability Projected in 2H 2023
Conference Call... More
